Use of molecular techniques for epidemiological typing of rapidly growing mycobacteria  by Esteban, J. et al.
cultures. As only two of the three university
hospitals had a laboratory information system in
the year 2000, the complete data were available
only for these two hospitals (the third hospital
only provided data concerning the number of
positive blood cultures and the number that were
positive for Strep. pneumoniae) (Table 1). Table 2
summarises the data for the other organisms
isolated in the two hospitals that provided these
data, with Staphylococcus epidermidis identified in
35.4% of cases, Staphylococcus aureus in 10%, and
Gram-negative bacteria in 24.5%. Of note, as we
focused on pneumococcal infections, the
Staph. epidermidis cases were not analysed to
determine the clinical relevance of the pathogen.
Moreover, the 464 cases with antibiotic treatment
for positive blood cultures and pathogens were
not analysed separately, but we agree that these
data would be interesting. The data from an
ongoing study will be analysed for these details
and we hope to present these data in the future.
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We read with interest the article in CMI by
Sampaio et al. [1], which described the use of
different methods for epidemiological typing of
rapidly growing mycobacteria. We agree with
the authors that molecular epidemiology is a
basic tool for gaining a better understanding of
the epidemiology of these organisms and their
role in human disease. However, the authors
stated that the randomly amplified polymorphic
DNA (RAPD) technique has a lower discrimi-
native power than ERIC-PCR or pulsed-field gel
electrophoresis (PFGE). This is not consistent
with our own recent experience in this area.
RAPD is a technique that has been described
for use with many species of bacteria, including
rapidly growing mycobacteria [2]. This tech-
nique has well-known problems concerning
reproducibility that have been described else-
where [3], but these problems can be addressed
by analysing all isolates on the same gel, and by
performing the experiments under rigorously
standardised conditions. The discriminative
power of the technique depends not only on
the primer set employed in the study [2], but
also on the number of primers used. In our own
experience using several primer sets [4], the
only isolates that give identical electrophoretic
profiles with at least three primer sets are those
that are epidemiologically related. If isolates are
analysed with only one primer set, there could
be false clustering of isolates that are epidem-
iologically unrelated, but these false clusters
disappear if additional primer sets are used.
Such an approach has been used in several
studies and has generated excellent results [5,6].
Sampaio et al. [1] used only one primer set, but
a combination of several primer sets may have
generated RAPD results that were at least
comparable with those of ERIC-PCR or PFGE.
The authors stated that other primer sets were
used, and it would be interesting to know
Table 2. Bacteria isolated from blood cultures of patients
with community-acquired pneumonia
Hospital 1 Hospital 2 Total
n % n % n %
Patients 302 494
Mortality 47 15.6% 70 14.2%
Blood cultures 168 55.6% 228 46.2%
Positive blood cultures 53 31.5% 57 25.0%
Bacteria isolated
Gram-negative bacteria 14 26.4% 13 22.8% 27 24.5%
Staphylococcus epidermidis 19 35.8% 20 35.1% 39 35.4%
Staphylococcus aureus 8 15.1% 3 5.3% 11 10.0%
Streptococcus pneumoniae 4 7.5% 2 3.5% 6 5.5%
Others 9 17.0% 15 26.3% 24 21.8%
Table 1. Blood cultures in three university hospitals in
North-Rhine Westphalia
Hospital Patients
Blood
cultures
Positive
blood
cultures
Blood cultures
positive for
Streptococcus
pneumoniae
1 302 168 53 2
2 494 228 57 4
3a 458 68 42 5
Total 1254 464 152 11
aHospital 3 provided data only for the number of positive blood cultures and the
number that were positive for Strep. pneumoniae.
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whether the combined results obtained with the
different primers were as discriminative as
those obtained with the techniques described
above, as has been found by others, including
ourselves.
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REPLY FROM DR SAMPAIO AND
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We thank Dr Esteban and colleagues for their
interesting comments. We had the opportunity
to read their article [4], and although it also
evaluated other rapidly growing mycobacteria,
our response here will be limited to Mycobacte-
rium fortuitum. In brief, they investigated 16 M.
fortuitum isolates using four different primers
and a single method, RAPD, modified from the
original protocol described by Zhang et al. [2];
however, ERIC-PCR or PFGE were not used.
Consequently, we disagree with their claim that
our results are not consistent with their own
experience in this area, as this is limited to
RAPD. We agree that RAPD analysis with
different primer sets may improve clonality
analysis, as described for Mycobacterium absces-
sus by Zhang et al. [2], although RAPD has
never been adequately validated for any of the
rapid growing mycobacteria as recommended
by the consensus guidelines of the ESCMID
Study Group for Epidemiological Markers [7].
We also tested M. fortuitum outbreak isolates
and unrelated control strains with primer OPA-
2, but we did not follow the protocol of Zhang
et al. [2], as this has not been validated for
M. fortuitum. When a combined analysis was
performed with profiles obtained with RAPD1
and OPA2, control strain C6, epidemiologically
unrelated to the outbreak, still clustered with
the outbreak isolates. This is why we stated that
PFGE and ERIC-PCR performed better than
RAPD in terms of discriminating among the
group of isolates and strains that we analysed
[1].
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